Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Carmine Therapeutics is raising $13,697,828.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Donald Haut played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Carmine Therapeutics
Carmine Therapeutics, headquartered in Cambridge MA, is pioneering a new class of non-viral gene therapies based on red blood cell extracellular vesicles, combined with proprietary payloads. In June 2020, Carmine inked a research alliance with Takeda Pharmaceuticals worth up to $900 million to develop non-viral gene therapies for 2 targets. Carmine has also been named one of the FierceBiotechs Fierce 15 Biotech companies of 2020 and was also awarded the Bristol-Myers Squibb Golden Ticket. Carmine was founded in 2019 by EVX Ventures, Professors Harvey Lodish (Whitehead, MIT), Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme and Millennium Pharmaceuticals, is also Chair of the Scientific Advisory Board of Carmine. .

To learn more about Carmine Therapeutics, visit http://www.carminetherapeutics.com/

Contact:
Donald Haut, Chief Executive Officer
978-289-7076

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved